ReNewVax has developed a vaccine discovery platform based on the exploitation of genomic analysis of real-world clinical samples, combined with
ex vivo human predictive models. Our lead program, RVX-001, is a best-in-class vaccine designed to induce universal immunity against pneumococcus infection, the most common cause of bacterial pneumonia and the largest pre-pandemic
vaccine market. Programs for Group A and Group B Streptococcus are in the pipeline – key pathogens in the fight against AntiMicrobial Resistance (AMR).
In murine models, RVX-001 was shown to protect against all strains tested. Our technology means that RVX-001 manufacturing costs are significantly lower than existing vaccines. These two factors combined address the key limitations of existing pneumococcal vaccines.
A virtual business model has been adopted, limiting overheads and utilizing an identified team of external advisors/contractors to access key expertise as required. Preclinical studies have provided robust proof-of-concept for RVX-001 and work is ongoing to consolidate our pre-CTA/pre-IND package. Initial clinical trials will commence in 2025. RVX-001 will initially target the lower-hurdle adult pneumococcal vaccine segment where it will attract significant market share from Merck's PPS23 and Pfizer’s PCV20 vaccines. With approval in that segment, label expansion into the £14.6bn paediatric market will then be sought.
ex vivo human predictive models. Our lead program, RVX-001, is a best-in-class vaccine designed to induce universal immunity against pneumococcus infection, the most common cause of bacterial pneumonia and the largest pre-pandemic
vaccine market. Programs for Group A and Group B Streptococcus are in the pipeline – key pathogens in the fight against AntiMicrobial Resistance (AMR).
In murine models, RVX-001 was shown to protect against all strains tested. Our technology means that RVX-001 manufacturing costs are significantly lower than existing vaccines. These two factors combined address the key limitations of existing pneumococcal vaccines.
A virtual business model has been adopted, limiting overheads and utilizing an identified team of external advisors/contractors to access key expertise as required. Preclinical studies have provided robust proof-of-concept for RVX-001 and work is ongoing to consolidate our pre-CTA/pre-IND package. Initial clinical trials will commence in 2025. RVX-001 will initially target the lower-hurdle adult pneumococcal vaccine segment where it will attract significant market share from Merck's PPS23 and Pfizer’s PCV20 vaccines. With approval in that segment, label expansion into the £14.6bn paediatric market will then be sought.
Speaker
